Sputum biomarkers in IPF: Evidence for raised gene expression and protein level of IGFBP-2, IL-8 and MMP-7

PLoS ONE

Volumn 12, Issue 2, 2017, Pages

  Guiot, J ^a   Henket, M ^a   Corhay, J L ^a   Moermans, C ^a   Louis, R ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL FACTOR; GELATINASE B; INTERLEUKIN 13; INTERLEUKIN 8; KL 6 PROTEIN; MATRILYSIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; YKL 40 PROTEIN; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CELL COUNT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE MARKER; EOSINOPHIL COUNT; EPITHELIUM CELL; FEMALE; FIBROSING ALVEOLITIS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IGFBP 2 GENE; IL 6 GENE; IL 8 GENE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MMP 7 GENE; NEUTROPHIL COUNT; RESPIRATORY TRACT INFLAMMATION; SPUTUM ANALYSIS; TOTAL LUNG CAPACITY; TRANSFORMING GROWTH FACTOR BETA GENE; TUMOR NECROSIS FACTOR ALPHA GENE; YKL 40 GENE; CYTOLOGY; GENETICS; IDIOPATHIC PULMONARY FIBROSIS; LEUKOCYTE COUNT; LUNG FUNCTION TEST; METABOLISM; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM;

BIOMARKERS; CROSS-SECTIONAL STUDIES; FEMALE; GENE EXPRESSION; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INTERLEUKIN-8; LEUKOCYTE COUNT; MALE; MATRIX METALLOPROTEINASE 7; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SPUTUM;

EID: 85012201562     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0171344     Document Type: Article

References (36)

1. Ganesh Raghu HRC, Egan Jim J., Martinez Fernando J., Behr Juergen, Brown Kevin K., Colby Thomas V., et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. American Journal of Respiratory and Critical Care Medicine. 2011; 183(6):788-824. doi: 10.1164/rccm.2009-040GL PMID: 21471066
2. Antoniou KM, Alexandrakis M, Tzanakis N, Tsiligianni I, Tzortzaki EG, Siafakas NM, et al. Induced sputum versus bronchoalveolar lavage fluid in the evaluation of patients with idiopathic pulmonary fibrosis. Respiration; international review of thoracic diseases. 2005; 72(1):32-8. doi: 10.1159/000083398 PMID: 15753632
3. Fireman E, Topilsky I, Greif J, Lerman Y, Schwarz Y, Man A, et al. Induced sputum compared to bronchoalveolar lavage for evaluating patients with sarcoidosis and non-granulomatous interstitial lung disease. Respiratory medicine. 1999; 93(11):827-34. PMID: 10603633
4. Fireman E, Lerman Y. Induced sputum in interstitial lung diseases. Current opinion in pulmonary medicine. 2006; 12(5):318-22. doi: 10.1097/01.mcp.0000239547.62949.82 PMID: 16926645
5. Antoniou KM, Tzortzaki EG, Alexandrakis MG, Zervou M, Tzanakis N, Sfiridaki K, et al. Investigation of IL-18 and IL-12 in induced sputum of patients with IPF before and after treatment with interferon gamma-1b. Sarcoidosis, vasculitis, and diffuse lung diseases: Official journal of WASOG / World Association of Sarcoidosis and Other Granulomatous Disorders. 2005; 22(3):204-9.
6. Balestro E, Calabrese F, Turato G, Lunardi F, Bazzan E, Marulli G, et al. Immune Inflammation and Disease Progression in Idiopathic Pulmonary Fibrosis. PloS one. 2016; 11(5):e0154516. doi: 10.1371/ journal.pone.0154516 PMID: 27159038
7. Vuga LJ, Milosevic J, Pandit K, Ben-Yehudah A, Chu Y, Richards T, et al. Cartilage oligomeric matrix protein in idiopathic pulmonary fibrosis. PloS one. 2013; 8(12):e83120. doi: 10.1371/journal.pone. 0083120 PMID: 24376648
8. Doubkova M, Karpisek M, Mazoch J, Skrickova J, Doubek M. Prognostic significance of surfactant protein A, surfactant protein D, Clara cell protein 16, S100 protein, trefoil factor 3, and prostatic secretory protein 94 in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease. Sarcoidosis, vasculitis, and diffuse lung diseases: Official journal of WASOG / World Association of Sarcoidosis and Other Granulomatous Disorders. 2016; 33(3):224-34.
9. Ohshimo S, Ishikawa N, Horimasu Y, Hattori N, Hirohashi N, Tanigawa K, et al. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis. Respiratory medicine. 2014; 108 (7):1031-9. doi: 10.1016/j.rmed.2014.04.009 PMID: 24835074
10. Samukawa T, Hamada T, Uto H, Yanagi M, Tsukuya G, Nosaki T, et al. The elevation of serum napsin A in idiopathic pulmonary fibrosis, compared with KL-6, surfactant protein-A and surfactant protein-D. BMC pulmonary medicine. 2012; 12:55. doi: 10.1186/1471-2466-12-55 PMID: 22963039
11. Ten Klooster L, van Moorsel CH, Kwakkel-van Erp JM, van Velzen-Blad H, Grutters JC. IgA in serum: An old acquaintance as a new prognostic biomarker in Idiopathic Pulmonary Fibrosis. Clinical and experimental immunology. 2015.
12. Tajiri M, Okamoto M, Fujimoto K, Johkoh T, Ono J, Tominaga M, et al. Serum level of periostin can predict long-term outcome of idiopathic pulmonary fibrosis. Respiratory investigation. 2015; 53(2):73-81. doi: 10.1016/j.resinv.2014.12.003 PMID: 25745852
13. Ley B, Brown KK, Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. American journal of physiology Lung cellular and molecular physiology. 2014; 307(9):L681-91. doi: 10.1152/ajplung. 00014.2014 PMID: 25260757
14. Guiot J, Bondue B, Henket M, Corhay JL, Louis R. Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis. BMC pulmonary medicine. 2016; 16(1):86. doi: 10.1186/s12890-016-0249-6 PMID: 27215343
15. Korthagen NM, van Moorsel CH, Barlo NP, Ruven HJ, Kruit A, Heron M, et al. Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis. Respiratory medicine. 2011; 105 (1):106-13. doi: 10.1016/j.rmed.2010.09.012 PMID: 20888745
16. Korthagen NM, van Moorsel CH, Zanen P, Ruven HJ, Grutters JC. Evaluation of circulating YKL-40 levels in idiopathic interstitial pneumonias. Lung. 2014; 192(6):975-80. doi: 10.1007/s00408-014-9647-9 PMID: 25274153
17. Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS medicine. 2008; 5(4):e93. doi: 10. 1371/journal.pmed.0050093 PMID: 18447576
18. Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med. 2001; 164(10 Pt 2):S28-38.
19. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013; 187(4):347-65. doi: 10.1164/rccm.201204-0596PP PMID: 22878278
20. Delvaux M, Henket M, Lau L, Kange P, Bartsch P, Djukanovic R, et al. Nebulised salbutamol administered during sputum induction improves bronchoprotection in patients with asthma. Thorax. 2004; 59 (2):111-5. doi: 10.1136/thorax.2003.011130 PMID: 14760148
21. da Silva J, Hilzendeger C, Moermans C, Schleich F, Henket M, Kebadze T, et al. Raised interferon beta, type 3 interferon and interferon stimulated genes-evidence of innate immune activation in neutrophilic asthma. Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology. 2016.
22. Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. The European respiratory journal. 2010; 36(3):646-54. doi: 10.1183/09031936.00095809 PMID: 20150207
23. Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al. General considerations for lung function testing. The European respiratory journal. 2005; 26(1):153-61. doi: 10.1183/09031936. 05.00034505 PMID: 15994402
24. Beeh KM, Beier J, Kornmann O, Buhl R. Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respiratory medicine. 2003; 97(6):634-9. PMID: 12814147
25. Domagala-Kulawik J, Skirecki T, Maskey-Warzechowska M, Grubek-Jaworska H, Chazan R. Bronchoalveolar lavage total cell count in interstitial lung diseases-does it matter? Inflammation. 2012; 35 (3):803-9. doi: 10.1007/s10753-011-9378-5 PMID: 21882075
26. Beeh KM, Beier J, Kornmann O, Buhl R. Neutrophilic inflammation in induced sputum of patients with idiopathic pulmonary fibrosis. Sarcoidosis, vasculitis, and diffuse lung diseases: Official journal of WASOG / World Association of Sarcoidosis and Other Granulomatous Disorders. 2003; 20(2):138-43.
27. Meloni F, Caporali R, Marone Bianco A, Paschetto E, Morosini M, Fietta AM, et al. BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis. Sarcoidosis, vasculitis, and diffuse lung diseases: Official journal of WASOG / World Association of Sarcoidosis and Other Granulomatous Disorders. 2004; 21(2):111-8.
28. Zuo F, Kaminski N, Eugui E, Allard J, Yakhini Z, Ben-Dor A, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99(9):6292-7. doi: 10.1073/pnas. 092134099 PMID: 11983918
29. Huh JW, Kim DS, Oh YM, Shim TS, Lim CM, Lee SD, et al. Is metalloproteinase-7 specific for idiopathic pulmonary fibrosis? Chest. 2008; 133(5):1101-6. doi: 10.1378/chest.07-2116 PMID: 18071010
30. Pardo A, Cabrera S, Maldonado M, Selman M. Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis. Respiratory research. 2016; 17:23. doi: 10.1186/s12931-016-0343-6 PMID: 26944412
31. Kobayashi J, Kitamura S. KL-6: a serum marker for interstitial pneumonia. Chest. 1995; 108(2):311-5. PMID: 7634858
32. Chadelat K, Boule M, Corroyer S, Fauroux B, Delaisi B, Tournier G, et al. Expression of insulin-like growth factors and their binding proteins by bronchoalveolar cells from children with and without interstitial lung disease. The European respiratory journal. 1998; 11(6):1329-36. PMID: 9657575
33. Moodley YP, Scaffidi AK, Misso NL, Keerthisingam C, McAnulty RJ, Laurent GJ, et al. Fibroblasts isolated from normal lungs and those with idiopathic pulmonary fibrosis differ in interleukin-6/gp130-mediated cell signaling and proliferation. The American journal of pathology. 2003; 163(1):345-54. doi: 10. 1016/S0002-9440(10)63658-9 PMID: 12819039
34. Moermans C, Heinen V, Nguyen M, Henket M, Sele J, Manise M, et al. Local and systemic cellular inflammation and cytokine release in chronic obstructive pulmonary disease. Cytokine. 2011; 56 (2):298-304. doi: 10.1016/j.cyto.2011.07.010 PMID: 21880505
35. Schnyder B, Bogdan JA Jr., Schnyder-Candrian S. Role of interleukin-8 phosphorylated kinases in stimulating neutrophil migration through fibrin gels. Laboratory investigation; a journal of technical methods and pathology. 1999; 79(11):1403-13. PMID: 10576211
36. Ziegenhagen MW, Zabel P, Zissel G, Schlaak M, Muller-Quernheim J. Serum level of interleukin 8 is elevated in idiopathic pulmonary fibrosis and indicates disease activity. Am J Respir Crit Care Med. 1998; 157(3 Pt 1):762-8.